http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Sep 2025 07:32:11 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html <p>Medicus Pharma Ltd. (NASDAQ: MDCX) has completed its acquisition of 98.6% of the issued and outstanding shares of Antev Limited for approximately $2.97 million in cash and 1,603,164 common shares of Medicus, according to a company statement.</p> <p>Antev, a UK-based clinical-stage drug development company, is developing Teverelix, a GnRH antagonist for acute urinary retention and prostate cancer treatment in patients with high cardiovascular risk. Former Antev shareholders are entitled to receive up to approximately $65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals.</p> <p>Patrick J. Mahaffy, former chairman of Antev and former CEO http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html Tue, 02 Sep 2025 07:32:11 -0500 CLVS MDCX PHRM http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html <p>Medicus Pharma Ltd. (NASDAQ: MDCX) has completed its acquisition of 98.6% of the issued and outstanding shares of Antev Limited for approximately $2.97 million in cash and 1,603,164 common shares of Medicus, according to a company statement.</p> <p>Antev, a UK-based clinical-stage drug development company, is developing Teverelix, a GnRH antagonist for acute urinary retention and prostate cancer treatment in patients with high cardiovascular risk. Former Antev shareholders are entitled to receive up to approximately $65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals.</p> <p>Patrick J. Mahaffy, former chairman of Antev and former CEO http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html Tue, 02 Sep 2025 07:32:11 -0500 CLVS MDCX PHRM http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html <p>Medicus Pharma Ltd. (NASDAQ: MDCX) has completed its acquisition of 98.6% of the issued and outstanding shares of Antev Limited for approximately $2.97 million in cash and 1,603,164 common shares of Medicus, according to a company statement.</p> <p>Antev, a UK-based clinical-stage drug development company, is developing Teverelix, a GnRH antagonist for acute urinary retention and prostate cancer treatment in patients with high cardiovascular risk. Former Antev shareholders are entitled to receive up to approximately $65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals.</p> <p>Patrick J. Mahaffy, former chairman of Antev and former CEO http://www.streetinsider.com/Mergers+and+Acquisitions/Medicus+Pharma+completes+%242.97+million+acquisition+of+Antev+Limited/25281212.html Tue, 02 Sep 2025 07:32:11 -0500 CLVS MDCX PHRM http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0500 CLVS MDCX PHRM http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0500 CLVS MDCX PHRM http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Press+Releases/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0500 CLVS MDCX PHRM http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0500 CLVS MDCX PHRM http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0500 CLVS MDCX PHRM http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html <p>Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunity</p><p style="text-align: center;"><i>Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors </i></p><p>Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("<b>Medicus</b>" or the "<b>Company</b>"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited ("<b>Antev</b>"), a UK-based clinical-stage drug development company, http://www.streetinsider.com/Newsfile/Medicus+Pharma+Ltd.+Completes+Acquisition+of+Antev+Limited/25281207.html Tue, 02 Sep 2025 07:30:00 -0500 CLVS MDCX PHRM http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html <p>PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced that the U.S. Food and Drug Administration approved its ketamine product KETARx on August 8, 2025, for surgical pain management applications.</p> <p>The Toronto-based specialty pharmaceutical company focuses on developing ketamine-based treatments for mental health, neurological, and pain disorders. The FDA approval provides a foundation for expanding ketamine development across these therapeutic areas within the company's pipeline, including depression, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Complex Regional Pain Syndrome.</p> <p>"Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html Mon, 11 Aug 2025 09:26:28 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html <p>PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced that the U.S. Food and Drug Administration approved its ketamine product KETARx on August 8, 2025, for surgical pain management applications.</p> <p>The Toronto-based specialty pharmaceutical company focuses on developing ketamine-based treatments for mental health, neurological, and pain disorders. The FDA approval provides a foundation for expanding ketamine development across these therapeutic areas within the company's pipeline, including depression, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Complex Regional Pain Syndrome.</p> <p>"Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html Mon, 11 Aug 2025 09:26:28 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html <p>PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced that the U.S. Food and Drug Administration approved its ketamine product KETARx on August 8, 2025, for surgical pain management applications.</p> <p>The Toronto-based specialty pharmaceutical company focuses on developing ketamine-based treatments for mental health, neurological, and pain disorders. The FDA approval provides a foundation for expanding ketamine development across these therapeutic areas within the company's pipeline, including depression, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Complex Regional Pain Syndrome.</p> <p>"Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html Mon, 11 Aug 2025 09:26:28 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html <p>PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced that the U.S. Food and Drug Administration approved its ketamine product KETARx on August 8, 2025, for surgical pain management applications.</p> <p>The Toronto-based specialty pharmaceutical company focuses on developing ketamine-based treatments for mental health, neurological, and pain disorders. The FDA approval provides a foundation for expanding ketamine development across these therapeutic areas within the company's pipeline, including depression, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Complex Regional Pain Syndrome.</p> <p>"Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html Mon, 11 Aug 2025 09:26:28 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html <p>PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced that the U.S. Food and Drug Administration approved its ketamine product KETARx on August 8, 2025, for surgical pain management applications.</p> <p>The Toronto-based specialty pharmaceutical company focuses on developing ketamine-based treatments for mental health, neurological, and pain disorders. The FDA approval provides a foundation for expanding ketamine development across these therapeutic areas within the company's pipeline, including depression, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Complex Regional Pain Syndrome.</p> <p>"Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html Mon, 11 Aug 2025 09:26:28 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html <p>PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced that the U.S. Food and Drug Administration approved its ketamine product KETARx on August 8, 2025, for surgical pain management applications.</p> <p>The Toronto-based specialty pharmaceutical company focuses on developing ketamine-based treatments for mental health, neurological, and pain disorders. The FDA approval provides a foundation for expanding ketamine development across these therapeutic areas within the company's pipeline, including depression, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Complex Regional Pain Syndrome.</p> <p>"Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html Mon, 11 Aug 2025 09:26:28 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html <p>PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced that the U.S. Food and Drug Administration approved its ketamine product KETARx on August 8, 2025, for surgical pain management applications.</p> <p>The Toronto-based specialty pharmaceutical company focuses on developing ketamine-based treatments for mental health, neurological, and pain disorders. The FDA approval provides a foundation for expanding ketamine development across these therapeutic areas within the company's pipeline, including depression, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Complex Regional Pain Syndrome.</p> <p>"Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html Mon, 11 Aug 2025 09:26:28 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html <p>PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced that the U.S. Food and Drug Administration approved its ketamine product KETARx on August 8, 2025, for surgical pain management applications.</p> <p>The Toronto-based specialty pharmaceutical company focuses on developing ketamine-based treatments for mental health, neurological, and pain disorders. The FDA approval provides a foundation for expanding ketamine development across these therapeutic areas within the company's pipeline, including depression, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Complex Regional Pain Syndrome.</p> <p>"Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html Mon, 11 Aug 2025 09:26:28 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html <p>PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced that the U.S. Food and Drug Administration approved its ketamine product KETARx on August 8, 2025, for surgical pain management applications.</p> <p>The Toronto-based specialty pharmaceutical company focuses on developing ketamine-based treatments for mental health, neurological, and pain disorders. The FDA approval provides a foundation for expanding ketamine development across these therapeutic areas within the company's pipeline, including depression, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Complex Regional Pain Syndrome.</p> <p>"Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global http://www.streetinsider.com/FDA/PharmaTher+receives+FDA+approval+for+ketamine+product+KETARx/25178835.html Mon, 11 Aug 2025 09:26:28 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html <p align="justify">TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved the Company’s ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achievement for PharmaTher and strategically positions the Company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html Mon, 11 Aug 2025 09:26:00 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html <p align="justify">TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved the Company’s ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achievement for PharmaTher and strategically positions the Company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html Mon, 11 Aug 2025 09:26:00 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html <p align="justify">TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved the Company’s ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achievement for PharmaTher and strategically positions the Company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html Mon, 11 Aug 2025 09:26:00 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html <p align="justify">TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved the Company’s ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achievement for PharmaTher and strategically positions the Company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html Mon, 11 Aug 2025 09:26:00 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html <p align="justify">TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved the Company’s ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achievement for PharmaTher and strategically positions the Company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html Mon, 11 Aug 2025 09:26:00 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html <p align="justify">TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved the Company’s ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achievement for PharmaTher and strategically positions the Company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html Mon, 11 Aug 2025 09:26:00 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html <p align="justify">TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved the Company’s ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achievement for PharmaTher and strategically positions the Company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards http://www.streetinsider.com/Press+Releases/PharmaTher+Announces+FDA+Approval+of+Ketamine+%28KETARx%E2%84%A2%29/25178832.html Mon, 11 Aug 2025 09:26:00 -0500 A.06822034 A.17568957 A.21823762 O.03307973 O.04889877 O.20026344 O.48931916 PHRM PHRRF